CASI Pharmaceuticals ’s Competitors, Revenue, Number of Employees, Funding, Acquisitions & News

CASI is a biopharmaceutical company that develops and commercializes therapeutics for the treatment of cancer. Read more

Wei-Wu He's photo - Chairman & CEO of CASI Pharmaceuticals

Chairman & CEO

Wei-Wu He

CEO Approval Rating

90/100

Founded:

1991

Status:

PublicNASDAQCASI

TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

NexImmune is a top competitor of CASI Pharmaceuticals . NexImmune was founded in 2011, and is headquartered in Gaithersburg, Maryland. Like CASI Pharmaceuticals , NexImmune also competes in the Biotechnology field. NexImmune generates $13.1M more revenue vs. CASI Pharmaceuticals .

bluebird bio is seen as one of CASI Pharmaceuticals 's top competitors. bluebird bio is headquartered in Cambridge, Massachusetts, and was founded in 1992. Like CASI Pharmaceuticals , bluebird bio also operates in the Biotechnology field. bluebird bio generates 2,696% the revenue of CASI Pharmaceuticals .

TScan has been one of CASI Pharmaceuticals 's top competitors. TScan's headquarters is in Waltham, Massachusetts, and was founded in 2018. Like CASI Pharmaceuticals , TScan also works within the Biotechnology industry. TScan generates 11% of CASI Pharmaceuticals 's revenue.

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Perthera a competitor of CASI Pharmaceuticals ?

Quarterly and Annual Revenue

Trailing 12-Months Trend (TTM)

Annual Revenue

$8.9M

CASI Pharmaceuticals 's revenue is the ranked 9th among it's top 10 competitors. The top 10 competitors average 1.6B. Over the last four quarters, CASI Pharmaceuticals 's revenue has decreased by 4.2%. Specifically, in Q2 2020's revenue was $2.7M; in Q1 2020, it was $3.4M; in Q4 2019, it was $1.3M; in Q3 2019, CASI Pharmaceuticals 's revenue was $2.8M.

Acquisitions

No recent acquisitions found related to CASI Pharmaceuticals

CASI Pharmaceuticals Funding History

$10M$45.4M$68.7M$167.2M$205.6M

Since CASI Pharmaceuticals was founded in 1991, it has participated in 8 rounds of funding. In total CASI Pharmaceuticals has raised $205.6M. CASI Pharmaceuticals 's last funding round was on Jul 2020 for a total of $38.0M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Private Placement
Jul 2020
$38M
-
Debt - PPP (CARES Act)
Apr 2020
$350K - $1M

U.S. Small Business Administration.

Private Placement
Sep 2018
$48.5M
-
Private Placement
Mar 2018
$50M
-
Private Placement
Oct 2017
$23.3M
-

Total Funding: $205.6M

Since CASI Pharmaceuticals was founded in 1991, it has participated in 8 rounds of funding. In total CASI Pharmaceuticals has raised $205.6M. CASI Pharmaceuticals 's last funding round was on Jul 2020 for a total of $38.0M

Investments

No recent investments found related to CASI Pharmaceuticals

CASI Pharmaceuticals News

July 22, 2020ChinaBio Today

CASI, a US-China Biopharma, Completes $38 Million Private Placement

CASI Pharma, a US biopharma developing products for China, raised $38 million in a private placement ... See more »
June 8, 2020MarketScreener

CASI Pharmaceuticals Announces Submission Of Clinical Trial Application (IND) To Conduct Phase 1 Study For Anti-38 Monoclonal Antibody Program

(marketscreener.com) ROCKVILLE, Md. and BEIJING, June 8, 2020 /PRNewswire/ -- CASI Pharmaceuticals, I... See more »
June 2, 2020MarketScreener

CASI Pharmaceuticals To Present At The Jefferies 2020 Healthcare Conference

(marketscreener.com) ROCKVILLE, Md., and BEIJING, June 2, 2020 /PRNewswire/ -- CASI Pharmaceuticals, ... See more »
May 18, 2020Zolmax News

AIM ImmunoTech (NYSE:AIM) vs. CASI Pharmaceuticals (NYSE:CASI) Head-To-Head Survey

CASI Pharmaceuticals (NASDAQ:CASI) and AIM ImmunoTech (NYSE:AIM) are both small-cap medical companies... See more »
May 12, 2020FinanzNachrichten

CASI Pharmaceuticals - Evomela strong despite COVID-19

CASI has made surprising progress despite COVID-19. The company reported Evomela sales of $3.37m in Q... See more »

CASI Pharmaceuticals Press Releases

October 31, 2017MarketersMedia

CASI Pharmaceuticals, Capital Raise, Analysts Review, Product Development, and Guidance

NEW YORK, NY / ACCESSWIRE / October 31, 2017 / Traders News Source, a leading independent equity rese... See more »
October 14, 2017streetinsider

CASI Pharmaceuticals Announces $23.8 Million Registered Direct Offering Led By Existing Shareholders

ROCKVILLE, Md., Oct. 13, 2017 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (the "Company") (Nasdaq: CAS... See more »
November 13, 2015PR NEWSWIRE

CASI Pharmaceuticals Reports Third Quarter 2015 Financial Results

ROCKVILLE, Md., Nov. 13, 2015 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmac... See more »
November 8, 2015PR NEWSWIRE

Data On Anti-Tumor Activity Of ENMD-2076 In Triple Negative Breast Cancer Animal Models Presented In Poster Session At AACR-NCI-EORTC International Conference

ROCKVILLE, Md., Nov. 8, 2015 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmace... See more »
November 6, 2015PR NEWSWIRE

Poster For ENMD-2076 Phase 2 Trial In Soft Tissue Sarcoma Presented At The 2015 Connective Tissue Oncology Society Annual Meeting

ROCKVILLE, Md., Nov. 5, 2015 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmace... See more »
November 4, 2015PR NEWSWIRE

CASI Pharmaceuticals Announces First Patient Dosed In Phase 2 Trial For ENMD-2076 In Fibrolamellar Carcinoma (FLC)

ROCKVILLE, Md., Nov. 4, 2015 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmace... See more »

CASI Pharmaceuticals Videos

Headquarters

9620 Medical Center Drive Suite 300

Rockville, Maryland20850

240-864-2600

Driving Directions »

Trending Companies

Summary

ABOUT

Overview

CASI is a biopharmaceutical company that develops and commercializes therapeutics for the treatment of cancer. CASI Pharmaceuticals was founded in 1991. CASI Pharmaceuticals 's headquarters is located in Rockville, Maryland, USA 20850. It has raised ...

CEO

CASI Pharmaceuticals 's Chairman & CEO, Wei-Wu He, currently has an approval rating of 90%. CASI Pharmaceuticals 's primary competitors are NexImmune, bluebird bio & TScan.

Website

casipharmaceuticals.com

Frequently Asked Questions about CASI Pharmaceuticals

  1. When was CASI Pharmaceuticals founded?

    CASI Pharmaceuticals was founded in 1991
  2. Who is CASI Pharmaceuticals 's CEO?

    CASI Pharmaceuticals 's CEO is Wei-Wu He
  3. How much revenue does CASI Pharmaceuticals generate?

    CASI Pharmaceuticals generates $8.9M in revenue
  4. How much funding does CASI Pharmaceuticals have?

    CASI Pharmaceuticals has historically raised $205.6M in funding
  1. Where is CASI Pharmaceuticals 's headquarters?

    CASI Pharmaceuticals 's headquarters is in Rockville Maryland, USA
  2. How many employees does CASI Pharmaceuticals have?

    CASI Pharmaceuticals has 125 employees
  3. What sector does CASI Pharmaceuticals operate in?

    CASI Pharmaceuticals is in Biotechnology
  4. Who are CASI Pharmaceuticals 's competitors?

    CASI Pharmaceuticals 's top competitors are NexImmune, bluebird bio, TScan